Companies

RELMADA THERAPEUTICS, INC. (RLMD) SEC filings

CIK 0001553643 · Pharmaceutical Preparations (SIC 2834) · Nasdaq · incorporated in NV · fiscal year ends 12/31

Annual financials (from the company's own XBRL in its 10-K filings)

FY2025FY2024FY2023FY2022
Revenue (USD)
Net income (USD)-157.0 M-125.8 M
Diluted EPS (USD/shares)-1.45-3.28-5.3

Latest filings

FiledFormDescriptionPeriod
2026-09-114OWNERSHIP DOCUMENT2026-09-09
2026-09-11442026-09-09
2026-09-088-KCURRENT REPORT items 8.012026-09-03
2026-08-14SCHEDULE 13G/ASCHEDULE 13G/A
2026-08-068-KCURRENT REPORT items 2.02,7.01,9.012026-08-06
2026-08-0610-QQUARTERLY REPORT2026-06-30
2026-07-29SCHEDULE 13GSCHEDULE 13G
2026-07-288-KCURRENT REPORT items 7.01,9.012026-07-28
2026-06-22SCHEDULE 13GSCHEDULE 13G
2026-06-18S-8REGISTRATION STATEMENT
2026-06-09SCHEDULE 13GSCHEDULE 13G
2026-05-288-KCURRENT REPORT items 5.03,5.07,9.012026-05-27
2026-05-13S-3ASRREGISTRATION STATEMENT
2026-05-13SCHEDULE 13G/ASCHEDULE 13G/A
2026-05-128-KCURRENT REPORT items 2.02,7.01,9.012026-05-12
2026-05-1210-QQUARTERLY REPORT2026-03-31
2026-05-04SCHEDULE 13GSCHEDULE 13G
2026-04-17DEFA14ADEFINITIVE ADDITIONAL MATERIALS
2026-04-17DEF 14APROXY STATEMENT2026-05-27
2026-04-09EFFECTEFFECT items ,,
2026-04-09424B3PROSPECTUS
2026-04-07CORRESPCORRESP
2026-04-07UPLOADUPLOAD
2026-04-06PRE 14APROXY STATEMENT2026-04-06
2026-04-03S-3REGISTRATION STATEMENT

Forms on file (last 1,000): 4 175, 8-K 148, 10-Q 40, SC 13G/A 23, SC 13G 21, 3 17, DEFA14A 17, CORRESP 15. Source: SEC EDGAR, as filed; this page is public data and not investment advice.

For software and AI agents: the same data as JSON, per call, no account: GET https://store.agentexchange.work/gw/filings/company?ticker=RLMD (0.002 USD), /gw/filings/filings?ticker=RLMD&form=8-K, /gw/filings/facts?ticker=RLMD&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txt

Updated from EDGAR within 30 minutes of a filing. Agent Exchange